Board of Directors


Christy Sandborg, MD

Board Chair
Professor of Pediatrics, Stanford University

The major emphasis of Dr. Sandborg’s work in the past decade has been focused on the future of academic pediatrics and pediatric rheumatology through providing training, research opportunities and environments to nurture and challenge future pediatric rheumatologists and subspecialists, and has now expanded to encompass design of new models of care for children with complex chronic illness.


Emily von Scheven, MD, MAS

UCSF Benioff Children’s Hospital

In 2001, as a young faculty member, Dr. von Scheven was invited to attend a small meeting at Stanford to discuss the development of a collaborative research network that would bring research to the patient, and vice versa. What she did not know at the time, was that the newly created network, called the Pediatric Rheumatology Research Network, would eventually become CARRA, and that CARRA would play a central role both in the pediatric rheumatology community and in her own professional life. CARRA has undergone tremendous growth, and has emerged as a respected, productive and well-supported organization with a broad constituent base. We now face new challenges, such as ensuring that our efforts are meaningful and impactful, that we stay focused on the priorities of our diverse community and that we address issues of sustainability.


Robert Colbert, MD, PhD

Vice President
Pediatric Rheumatologist
Bethesda, Maryland

Dr. Colbert served as the director of the Division of Rheumatology at Cincinnati Children's Hospital Medical Center (CCHMC) of the University of Cincinnati College of Medicine (UCCOM). He is certified in pediatric rheumatology by the American Board of Pediatrics and holds memberships in the American Academy of Pediatrics, the American Association of Immunologists, the American College of Rheumatology, the Society for Pediatric Research, and the American Pediatric Society. His research career has included authoring 53 papers and serving as an investigator on a number of NIAMS and other NIH and industry-funded research studies. Dr. Colbert’s accomplishments have been recognized in numerous honors and awards, including Pfizer Postdoctoral Fellowship and Scholar Awards, the James R. Klinenberg Science Award from the Arthritis Foundation, and the American College of Rheumatology’s Deborah Kredich Pediatric Rheumatology Service Award.


Stacy Ardoin, MD

Nationwide Children's Hospital

 Stacy Ardoin serves on CARRA’s Executive Committee of the Board as CARRA Treasurer. She is a pediatric and adult rheumatologist with more than 20 years of experience and is the Chair of Rheumatology at Nationwide Children’s Hospital. As a clinician and clinician research scientist in adult and pediatric rheumatology, her research centers on the transition from pediatric to adult care and on the long-term complications of adult and childhood lupus. She previously served as the elected SLE Committee Chair for CARRA from 2015 to 2018. 

“I have been an active CARRA member since I started my internal medicine/pediatrics rheumatology fellowship in 2002, and it has been inspiring to see how CARRA has grown and matured into a large, dynamic research organization representing the vast majority of North American pediatric rheumatologists.”


Rob Fuhlbrigge MD, PhD

Past President
Children’s Hospital Colorado  

Following 20+ years at Boston Children’s Hospital, Dr. Fuhlbrigge moved to Denver in 2016 where he is currently Professor of Pediatrics at the University of Colorado - Denver and Section Chief for Pediatric Rheumatology at Children’s Hospital Colorado. He is the current Chair for CARRA and former Vice Chair, Finance Chair and Treasurer. Prior to that he served 2 terms as Chair of the Scleroderma, Vasculitis and Rare Diseases Committee and he continues as an active member of several research workgroups within this committee. In these varied roles, he has been closely involved with the operations of the CARRA research enterprise and a key contributor to strategic initiatives implemented over the past 5 years.


Harry Saal, PhD

Retrotope, Inc.

Dr. Harry J. Saal was the founder and CEO of Network General Corporation, the first company wholly dedicated to the area of network diagnostics and the creator of the eponymous "Sniffer" network analyzer. In 2002, Dr. Saal was chosen by the US Department of Justice to lead the Technical Committee charged with monitoring and enforcing the Microsoft Antitrust case. He served as Chairman of the Committee through the May 2011 expiration of the Judgment.

Most recently, he is the Chair of Retrotope, Inc. a pharmaceutical startup, based here in Silicon Valley. Dr. Saal is confident that the compounds under development stand an excellent chance of revolutionizing the treatment and prevention of a wide variety of untreatable neurodegenerative diseases of aging.


Carol Wallace, MD

Professor Emeritus, University of Washington

Dr. Wallace received her MD from the University of Michigan in 1973. She completed both her residency in pediatrics and fellowship in pediatric rheumatology at the University of Washington. Following this, she was in private practice pediatrics and rheumatology until she joined the University of Washington and Children’s Hospital and Regional Medical Center in 1984. Dr. Wallace’s main focus has been the aggressive treatment of Juvenile Idiopathic Arthritis (JIA) and other Pediatric Rheumatic Diseases. She has published many of the sentinel studies of the use of methotrexate in the treatment of JIA.


Leigh White, JD

Leigh White is an investor and business advisor to start up companies in Silicon Valley. Previously she served as Executive Vice President at CurAgeis Technologies, responsible for building the company’s fatigue management division around new leading edge scientific technology. She joined CurAegis (pronounced like “courageous”) in September 2015 after 6 years as President of Alertness Solutions – a leading fatigue management firm with significant focus on the aviation industry.

Prior to acquiring Alertness Solutions, she spent 14 years as a Silicon Valley venture capital investor. Ms. White holds a Bachelor’s Degree in Finance from Wichita State University. She earned her J.D. from Stanford Law School in 1996 and is a member of the State Bar of California.

Daniel H. Solomon, MD, MPH

Daniel Solomon is a Professor of Medicine and Chief of the Section Clinical Sciences in the Division of Rheumatology at Brigham and Women’s Hospital (BWH). He holds the Matthew H. Liang Distinguished Chair in Arthritis and Population Health at BWH. Solomon earned his BA and MD degrees at Yale University, MPH at Harvard University and completed his residency in internal medicine and fellowship in rheumatology at BWH. His early work focused on the safety of NSAIDs and selective COX-2 inhibitors, and he continues to study analgesics. Solomon’s current research focuses on cardiovascular disease in rheumatoid arthritis, and he is the co-Principal Investigator on an NIH funded trial testing the effect of disease-modifying antirheumatic drugs (DMARDs) on cardiovascular disease, also known as the TARGET trial. He also has several ongoing projects improving implementation of treat to target in rheumatoid arthritis.

He has published over 400 original articles, 60 editorials and book chapters, and has been PI on numerous NIH, foundation, and industry supported grants. He will be the next Editor in Chief of Arthritis & Rheumatology. As well, he is the Chair of the FDA Arthritis Advisory Committee. He is also the PI of the VERITY P30 Clinical Research Core at BWH which aims to improve clinical research in rheumatology.

In addition to his investigative achievements, Solomon has a busy clinical practice and has played a special role in helping the Hispanic community and been instrumental in advancing the collaborative clinical Cardiovascular in Rheumatology Medicine practice at BWH. Solomon has mentored over 35 trainees and junior faculty and was recently awarded The Baughman Faculty Mentoring Award at BWH.


John Sundy, MD, PhD

Chief Medical Officer, Pandion Therapeutics

 John Sundy is an adult rheumatologist and immunologist with over 25 years of academic and industry experience developing therapies for inflammatory and fibrotic diseases. His research has focused on translational research and clinical trials of novel therapies for a broad variety of immunologic and inflammatory diseases. Dr. Sundy is currently the Chief Medical Officer at Pandion Therapeutics where he leads the clinical development of innovative modular biologic medicines targeting severe inflammatory and autoimmune diseases. Dr. Sundy previously served as Senior Vice President and Inflammation Therapeutic Area Head at Gilead Sciences, where he was responsible for Phase 1-4 development of over a dozen novel therapeutics, including completion of Phase 3 trials for the JAK inhibitor filgotinib filed worldwide in RA. He also was an Associate Professor of Medicine with tenure at Duke University and the Duke-National University of Singapore Graduate Medical School. At Duke he held several leadership roles including Associate Director of the Duke Clinical Research Institute (DCRI) and Director of Duke's Global Proof of Concept Research Unit Network. 

He has longstanding affinity for CARRA having been involved with the organization at the time

that initial NIAMS funding for the CARRA Legacy Registry was awarded. Working in collaboration with Drs. Schanberg, Sandborg, Wallace and Kimura he gained an appreciation for the particular challenges that pediatric rheumatologists face in both clinical practice and in research. “

He is currently an Adjunct Professor of Medicine at Duke University, and has been board certified in Internal Medicine, Rheumatology and Allergy/Immunology.

“What has been remarkable to me is the cooperation and dedication that pediatric rheumatology community has demonstrated in coalescing around CARRA. Having devoted most of my academic and industry research efforts to novel therapeutics, I am interested in contributing to the CARRA mission by facilitating access to research for children with rheumatologic diseases.”